Milnacipran: Beyond a role of antidepressant

Chi Un Pae, David M. Marks, Manan Shah, Changsu Han, Byung-Joo Ham, Ashwin A. Patkar, Prakash S. Masand

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, venlafaxine, desvenlafaxine, and duloxetine such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses. The half-life of milnacipran is approximately 8 hours. In addition, milnacipran does not inhibit the cytochrome P 450 system, indicating minimal propensity for drug-drug interactions. The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. Moreover, evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms. The current paper reviews researches conducted to date that is relevant to the efficacy, tolerability, and mechanism of action of milnacipran in the treatment of depression, fibromyalgia, and other psychiatric syndromes. Future directions of research are also identified.

Original languageEnglish
Pages (from-to)355-363
Number of pages9
JournalClinical Neuropharmacology
Volume32
Issue number6
DOIs
Publication statusPublished - 2009 Nov 1

Fingerprint

Antidepressive Agents
Fibromyalgia
Controlled Clinical Trials
Major Depressive Disorder
milnacipran
Drug Interactions
Research
Cytochrome P-450 Enzyme System
Fatigue
Psychiatry
Half-Life
Serotonin
Norepinephrine
Therapeutics
Anxiety
Pharmacokinetics
Placebos
Depression
Pharmaceutical Preparations

Keywords

  • Antidepressant
  • Anxiety
  • Fatigue
  • Fibromyalgia
  • Milnacipran
  • Pain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Pae, C. U., Marks, D. M., Shah, M., Han, C., Ham, B-J., Patkar, A. A., & Masand, P. S. (2009). Milnacipran: Beyond a role of antidepressant. Clinical Neuropharmacology, 32(6), 355-363. https://doi.org/10.1097/WNF.0b013e3181ac155b

Milnacipran : Beyond a role of antidepressant. / Pae, Chi Un; Marks, David M.; Shah, Manan; Han, Changsu; Ham, Byung-Joo; Patkar, Ashwin A.; Masand, Prakash S.

In: Clinical Neuropharmacology, Vol. 32, No. 6, 01.11.2009, p. 355-363.

Research output: Contribution to journalArticle

Pae, CU, Marks, DM, Shah, M, Han, C, Ham, B-J, Patkar, AA & Masand, PS 2009, 'Milnacipran: Beyond a role of antidepressant', Clinical Neuropharmacology, vol. 32, no. 6, pp. 355-363. https://doi.org/10.1097/WNF.0b013e3181ac155b
Pae, Chi Un ; Marks, David M. ; Shah, Manan ; Han, Changsu ; Ham, Byung-Joo ; Patkar, Ashwin A. ; Masand, Prakash S. / Milnacipran : Beyond a role of antidepressant. In: Clinical Neuropharmacology. 2009 ; Vol. 32, No. 6. pp. 355-363.
@article{863e8892f3584702b56d4902971d199b,
title = "Milnacipran: Beyond a role of antidepressant",
abstract = "Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, venlafaxine, desvenlafaxine, and duloxetine such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses. The half-life of milnacipran is approximately 8 hours. In addition, milnacipran does not inhibit the cytochrome P 450 system, indicating minimal propensity for drug-drug interactions. The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. Moreover, evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms. The current paper reviews researches conducted to date that is relevant to the efficacy, tolerability, and mechanism of action of milnacipran in the treatment of depression, fibromyalgia, and other psychiatric syndromes. Future directions of research are also identified.",
keywords = "Antidepressant, Anxiety, Fatigue, Fibromyalgia, Milnacipran, Pain",
author = "Pae, {Chi Un} and Marks, {David M.} and Manan Shah and Changsu Han and Byung-Joo Ham and Patkar, {Ashwin A.} and Masand, {Prakash S.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1097/WNF.0b013e3181ac155b",
language = "English",
volume = "32",
pages = "355--363",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Milnacipran

T2 - Beyond a role of antidepressant

AU - Pae, Chi Un

AU - Marks, David M.

AU - Shah, Manan

AU - Han, Changsu

AU - Ham, Byung-Joo

AU - Patkar, Ashwin A.

AU - Masand, Prakash S.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, venlafaxine, desvenlafaxine, and duloxetine such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses. The half-life of milnacipran is approximately 8 hours. In addition, milnacipran does not inhibit the cytochrome P 450 system, indicating minimal propensity for drug-drug interactions. The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. Moreover, evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms. The current paper reviews researches conducted to date that is relevant to the efficacy, tolerability, and mechanism of action of milnacipran in the treatment of depression, fibromyalgia, and other psychiatric syndromes. Future directions of research are also identified.

AB - Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, venlafaxine, desvenlafaxine, and duloxetine such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses. The half-life of milnacipran is approximately 8 hours. In addition, milnacipran does not inhibit the cytochrome P 450 system, indicating minimal propensity for drug-drug interactions. The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. Moreover, evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms. The current paper reviews researches conducted to date that is relevant to the efficacy, tolerability, and mechanism of action of milnacipran in the treatment of depression, fibromyalgia, and other psychiatric syndromes. Future directions of research are also identified.

KW - Antidepressant

KW - Anxiety

KW - Fatigue

KW - Fibromyalgia

KW - Milnacipran

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=73349096343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349096343&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3181ac155b

DO - 10.1097/WNF.0b013e3181ac155b

M3 - Article

C2 - 19620845

AN - SCOPUS:73349096343

VL - 32

SP - 355

EP - 363

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 6

ER -